News

All existing investors, including Third Rock Ventures, GV, SR One, and Regeneron Pharmaceuticals, participated in the round, and were joined by new investors including Foresite Capital, Bessemer Trust,

However, the company is positive on the outcome of the trial with its final analysis, which is based on survival, delayed due to the unexpected longevity of the

Part of the government’s modern industrial strategy, the Scottish project will secure £13m funding from the Industrial Strategy Challenge Fund. The funding is offered by UK Research and

BridgeBio also announced that it has launched a subsidiary company Fortify Therapeutics to further develop this chemistry for local treatment of Leber's Hereditary Optic Neuropathy (LHON), with an

The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than

Germany-based Evotec will also get licenses of a majority of infectious disease research portfolio and initiatives of Sanofi as per the terms of the transaction agreement. Sanofi has

WHIM syndrome is a primary immunodeficiency disease caused by a mutation in the C-X-C receptor type 4 (CXCR4) gene, which results in susceptibility to certain types of infections. The

Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients treated with EPd compared with pomalidomide and dexamethasone (Pd) alone. ELOQUENT-3 is